Bonesupport Ab (publ)(FRA) 2B4

Bonesupport Holding AB (publ) is a specialized orthobiologics firm focused on the development and global commercialization of injectable bioceramic bone graft substitutes. The company aims to effectively treat bone voids with innovative solutions distributed across Europe, North America, and other international markets.

Products and Services

• CERAMENT Bone Void Filler, a moldable and drillable synthetic material
• CERAMENT G, a ceramic bone graft substitute infused with gentamicin
• CERAMENT V, a synthetic bone void filler containing vancomycin

Growth Outlook

• Revenue increased to SEK 355.7 million in Q2 2026, up from SEK 324 million in Q1 2026
• Gross profit margin remains strong at 90.8% in Q2 2026
• Active preclinical research aims to expand product offerings in bone regeneration

Financial Highlights

• Net income of SEK 81.9 million reported in Q2 2026, reflecting a 23% net income ratio
• Current ratio stands at 5.44, indicating strong liquidity
• Operating income margin of 25.2% in Q2 2026 demonstrates operational efficiency

Bonesupport Holding AB (publ) is positioned in the healthcare sector, specifically within medical instruments and supplies. The company has shown consistent revenue growth, with a notable increase in Q2 2026 compared to the previous quarter. The strong gross profit margin indicates effective cost management and product demand. With a robust current ratio, Bonesupport maintains a solid liquidity position, allowing for potential investments in research and development. The ongoing preclinical research efforts suggest a commitment to innovation and expansion in the orthobiologics market, targeting various challenging medical conditions. Overall, Bonesupport presents a compelling opportunity for investors interested in the healthcare sector, particularly in advanced medical solutions.